Abstract
Objective. To examine whether chronic oral treatment with an angiotensin-converting enzyme inhibitor imidapril and an angiotensin II type 1 receptor antagonist TCV-116 would alter the response to angiotensin II in the rostral ventrolateral medulla. Methods. Twelve-week-old spontaneously hypertensive rats (SHR) were treated with imidapril (20 mg/kg per day, n = 7), TCV-I16 (5 mg/kg per day, n = 8) or vehicle (n = 8) for 4 weeks. Wistar-Kyoto rats (WKY) (n = 8) served as normotensive controls. At 16 weeks of age, angiotensin II (100 pmol) was microinjected into the rostral ventrolateral medulla of anaesthetized rats. Results. Blood pressure decreased significantly in the rats treated with either imidapril or TCV-116. Presser responses to angiotensin II microinjected into the rostral ventrolateral medulla were comparable in the untreated SHR, the imidapril-treated SHR and WKY (12 ± 2, 15 ± 4 and 10 ± 1 mmHg, respectively), but were abolished in SHR treated with TCV-116 (0 ± 2 mmHg, P < 0.01). Angiotensin-converting enzyme activity in the brain stem was significantly lower in SHR treated with imidapril (0.70 ± 0.06 nmol/mg per h), but significantly higher in SHR treated with TCV-116 (1.62 ± 0.04 nmol/mg per h) than in the untreated SHR (1.37 ± 0.05 nmol/mg per h). Conclusions. Chronic oral treatment with imidapril and TCV-116 may have divergent influences on the renin-angiotensin system within the brain stem. TCV-116, but not imidapril, abolishes the presser effect of angiotensin II in the rostral ventrolateral medulla.
| Original language | English |
|---|---|
| Pages (from-to) | 917-922 |
| Number of pages | 6 |
| Journal | Journal of Hypertension |
| Volume | 17 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 21 1999 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Physiology
- Cardiology and Cardiovascular Medicine
Cite this
Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. / Tsuchihashi, Takuya; Kagiyama, Shuntaro; Matsumura, Kiyoshi; Abe, Isao; Fujishima, Masatoshi.
In: Journal of Hypertension, Vol. 17, No. 7, 21.07.1999, p. 917-922.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR
AU - Tsuchihashi, Takuya
AU - Kagiyama, Shuntaro
AU - Matsumura, Kiyoshi
AU - Abe, Isao
AU - Fujishima, Masatoshi
PY - 1999/7/21
Y1 - 1999/7/21
N2 - Objective. To examine whether chronic oral treatment with an angiotensin-converting enzyme inhibitor imidapril and an angiotensin II type 1 receptor antagonist TCV-116 would alter the response to angiotensin II in the rostral ventrolateral medulla. Methods. Twelve-week-old spontaneously hypertensive rats (SHR) were treated with imidapril (20 mg/kg per day, n = 7), TCV-I16 (5 mg/kg per day, n = 8) or vehicle (n = 8) for 4 weeks. Wistar-Kyoto rats (WKY) (n = 8) served as normotensive controls. At 16 weeks of age, angiotensin II (100 pmol) was microinjected into the rostral ventrolateral medulla of anaesthetized rats. Results. Blood pressure decreased significantly in the rats treated with either imidapril or TCV-116. Presser responses to angiotensin II microinjected into the rostral ventrolateral medulla were comparable in the untreated SHR, the imidapril-treated SHR and WKY (12 ± 2, 15 ± 4 and 10 ± 1 mmHg, respectively), but were abolished in SHR treated with TCV-116 (0 ± 2 mmHg, P < 0.01). Angiotensin-converting enzyme activity in the brain stem was significantly lower in SHR treated with imidapril (0.70 ± 0.06 nmol/mg per h), but significantly higher in SHR treated with TCV-116 (1.62 ± 0.04 nmol/mg per h) than in the untreated SHR (1.37 ± 0.05 nmol/mg per h). Conclusions. Chronic oral treatment with imidapril and TCV-116 may have divergent influences on the renin-angiotensin system within the brain stem. TCV-116, but not imidapril, abolishes the presser effect of angiotensin II in the rostral ventrolateral medulla.
AB - Objective. To examine whether chronic oral treatment with an angiotensin-converting enzyme inhibitor imidapril and an angiotensin II type 1 receptor antagonist TCV-116 would alter the response to angiotensin II in the rostral ventrolateral medulla. Methods. Twelve-week-old spontaneously hypertensive rats (SHR) were treated with imidapril (20 mg/kg per day, n = 7), TCV-I16 (5 mg/kg per day, n = 8) or vehicle (n = 8) for 4 weeks. Wistar-Kyoto rats (WKY) (n = 8) served as normotensive controls. At 16 weeks of age, angiotensin II (100 pmol) was microinjected into the rostral ventrolateral medulla of anaesthetized rats. Results. Blood pressure decreased significantly in the rats treated with either imidapril or TCV-116. Presser responses to angiotensin II microinjected into the rostral ventrolateral medulla were comparable in the untreated SHR, the imidapril-treated SHR and WKY (12 ± 2, 15 ± 4 and 10 ± 1 mmHg, respectively), but were abolished in SHR treated with TCV-116 (0 ± 2 mmHg, P < 0.01). Angiotensin-converting enzyme activity in the brain stem was significantly lower in SHR treated with imidapril (0.70 ± 0.06 nmol/mg per h), but significantly higher in SHR treated with TCV-116 (1.62 ± 0.04 nmol/mg per h) than in the untreated SHR (1.37 ± 0.05 nmol/mg per h). Conclusions. Chronic oral treatment with imidapril and TCV-116 may have divergent influences on the renin-angiotensin system within the brain stem. TCV-116, but not imidapril, abolishes the presser effect of angiotensin II in the rostral ventrolateral medulla.
UR - http://www.scopus.com/inward/record.url?scp=0033024799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033024799&partnerID=8YFLogxK
U2 - 10.1097/00004872-199917070-00007
DO - 10.1097/00004872-199917070-00007
M3 - Article
VL - 17
SP - 917
EP - 922
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 7
ER -